Latest Deals

Credit: Shutterstock/anhdung.

Abcam’s $5.7bn acquisition by multi-national conglomerate Danaher may be blocked by shareholders after the company’s founder declared his intention to vote against the deal. Jonathan Milner, founder and ex-CEO of the UK-based antibody and protein manufacturer, announced that he believed the $24 per share pricing “substantially undervalues” the company, and called for a replacement of the company’s board. The deal was originally signed in late August 2023, and received unanimous backing from the boards of directors of both companies.

Nearly one year on from announcing it had agreed to acquire drug-eluting balloon company MedAlliance, Cordis has completed the takeover in a deal that could surpass $1bn, depending on the attainment of certain milestones. 

Cordis, who has a range of cardiovascular devices, including percutaneous transluminal angioplasty (PTA) balloons, will pay an upfront closing payment of $200m and an investment of $35m to Swiss-based MedAlliance.

Private equity firm, Cinven, has made a move to buy out the remaining shares of the Germany-based diagnostics company, Synlab, valuing the company at €2.24 billion ($2.37 billion). The UK-based equity firm has long since owned 43% of the firm but seeks now to acquire the remainder of its shares, offering €10 a share.

Harbinger Health has raised $140m in a Series B funding round, which will enable the completion of the study of its first blood-based screening product for cancer. Harbinger will use this financing to complete a clinical study of its new cancer screening platform, HarbingerHx, involving 10,000 participants.